Savara (SVRA) Change in Cash (2010 - 2026)
Savara (SVRA) reported Change in Cash of $5.6 million for Q1 2026, up 26.72% year-over-year from $4.4 million in Q1 2025, and down 66.8% on a QoQ basis from $16.9 million in Q4 2025.
Savara (SVRA) has 17 years of Change in Cash data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Change in Cash rose 26.72% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.2 million (up 594.15% YoY) and the FY2025 annual result came in at $18.1 million, up 257.56% from the prior year.
- Change in Cash fell to $5.6 million in Q1 2026 per SVRA's latest filing, from $16.9 million in the prior quarter.
- Across five years, Change in Cash topped out at $45.2 million in Q1 2022 and bottomed at -$67.7 million in Q4 2022.
- The 5-year median for Change in Cash is -$1.1 million (2023), against an average of $281117.6.
- Peak annual rise in Change in Cash reached 510.18% in 2022, while the deepest fall reached 533.86% in 2022.
- Tracing SVRA's Change in Cash over 5 years: stood at -$67.7 million in 2022, then jumped by 98.37% to -$1.1 million in 2023, then plunged by 470.05% to -$6.3 million in 2024, then surged by 368.34% to $16.9 million in 2025, then tumbled by 66.8% to $5.6 million in 2026.
- Per Business Quant, the three latest SVRA Change in Cash figures stand at $5.6 million (Q1 2026), $16.9 million (Q4 2025), and -$1.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 5.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.61 Mn |
| Dec 31, 2025 | 16.90 Mn |
| Sep 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | -6.30 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | 7.08 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Dec 31, 2023 | -1.11 Mn |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | -11.24 Mn |
| Mar 31, 2023 | -18.12 Mn |
| Dec 31, 2022 | -67.74 Mn |
| Sep 30, 2022 | 24.69 Mn |
| Jun 30, 2022 | 15.93 Mn |
| Mar 31, 2022 | 45.22 Mn |
| Dec 31, 2021 | -10.69 Mn |
| Sep 30, 2021 | 4.05 Mn |
| Jun 30, 2021 | -15.33 Mn |
| Mar 31, 2021 | 33.10 Mn |
| Dec 31, 2020 | -12.34 Mn |
| Sep 30, 2020 | -11.90 Mn |
| Jun 30, 2020 | 12.60 Mn |
| Mar 31, 2020 | -15.29 Mn |
| Dec 31, 2019 | 32.02 Mn |
| Sep 30, 2019 | 955,000.00 |
| Jun 30, 2019 | -8.84 Mn |
| Mar 31, 2019 | 1.37 Mn |
| Dec 31, 2018 | -645,000.00 |
| Sep 30, 2018 | 1.34 Mn |
| Jun 30, 2018 | 1.48 Mn |
| Mar 31, 2018 | 1,000.00 |
| Dec 31, 2017 | 2.31 Mn |
| Sep 30, 2017 | -41.32 Mn |
| Jun 30, 2017 | 50.67 Mn |
| Mar 31, 2017 | -2.91 Mn |
| Dec 31, 2016 | -2.14 Mn |
| Sep 30, 2016 | 1.45 Mn |
| Jun 30, 2016 | -3.09 Mn |
| Mar 31, 2016 | 469,000.00 |
| Dec 31, 2015 | 7.60 Mn |
| Sep 30, 2015 | 10.99 Mn |
| Jun 30, 2015 | -6.72 Mn |
| Mar 31, 2015 | -7.87 Mn |
| Dec 31, 2014 | 9.83 Mn |
| Sep 30, 2014 | -386,000.00 |
| Jun 30, 2014 | -3.48 Mn |
| Mar 31, 2014 | 4.17 Mn |
| Dec 31, 2013 | -4.55 Mn |
| Sep 30, 2013 | -14.74 Mn |
| Jun 30, 2013 | 23.56 Mn |
| Mar 31, 2013 | -1.09 Mn |
| Dec 31, 2012 | -3.59 Mn |
| Sep 30, 2012 | -3.87 Mn |
| Jun 30, 2012 | -5.09 Mn |
| Mar 31, 2012 | -8.52 Mn |
| Dec 31, 2011 | 10.80 Mn |
| Sep 30, 2011 | -9.19 Mn |
| Jun 30, 2011 | -4.60 Mn |
| Mar 31, 2011 | 18.57 Mn |
| Dec 31, 2010 | -1.35 Mn |
| Sep 30, 2010 | -1.83 Mn |